BG-68501 + fulvestrant + BGB-43395

This is a **combination regimen** of three investigational agents: **BG-68501** (also known as ETX-197, a CDK2 inhibitor), **fulvestrant** (a selective estrogen receptor degrader with established use in hormone receptor-positive breast cancer), and **BGB-43395** (an orally available, potent, and highly selective CDK4 inhibitor). The combination is currently under early-phase clinical investigation, specifically in patients with hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer. The regimen is designed to co-target key drivers of proliferation in breast cancer: cyclin-dependent kinase 2 (CDK2) and cyclin-dependent kinase 4 (CDK4), alongside estrogen receptor pathway inhibition. BG-68501 acts by selectively inhibiting CDK2, BGB-43395 acts by selective CDK4 inhibition (minimizing CDK6-associated toxicity like neutropenia), and fulvestrant works by degrading estrogen receptors, suppressing estrogen-dependent tumor growth. The regimen is being evaluated for safety, tolerability, pharmacokinetics, and preliminary efficacy in advanced breast cancer. BeiGene is the principal developer and sponsor for BG-68501 and BGB-43395; fulvestrant is a marketed drug developed by AstraZeneca[1][2][3][4].